On Nov 08, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $111 to $115.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $106 to $111.
TD Cowen analyst Tyler Van Buren maintains with a buy rating.
William Blair analyst Sami Corwin maintains with a buy rating.
H.C. Wainwright analyst Emily Bodnar maintains with a buy rating, and adjusts the target price from $95 to $115.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The probability of success for anito-cel has been revised upwards after reviewing the preliminary results from the Phase 2 iMMagine-1 trial in patients with relapsed/refractory multiple myeloma. There is a significant opportunity for market share capture, first targeting treatment in later stages and potentially in earlier stages if the current clinical outcomes are maintained.
The firm's analysis suggests that recent abstracts, which encompass initial Phase 2 results and extended Phase 1 data, support the competitive position and regulatory progress of pivotal-stage anito-cel in treating multiple myeloma. Despite a decline in share value, this is perceived as a 'sell the news' event following a substantial pre-abstract increase. It is now anticipated that anito-cel will secure a more formidable peak market share and exhibit greater likelihood of success.
The firm expressed increasing optimism following the updated clinical data release. The publication of ASH abstracts, notably the initial data from the registrational IMMagine-1 study, contributed to this positive outlook.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月8日，多家華爾街大行更新了$Arcellx (ACLX.US)$的評級，目標價介於111美元至115美元。
摩根士丹利分析師Judah Frommer維持買入評級，並將目標價從106美元上調至111美元。
TD Cowen分析師Tyler Van Buren維持買入評級。
威廉博萊分析師Sami Corwin維持買入評級。
H.C. Wainwright分析師Emily Bodnar維持買入評級，並將目標價從95美元上調至115美元。
此外，綜合報道，$Arcellx (ACLX.US)$近期主要分析師觀點如下：
通過重新審視第2期iMMagine-1臨床試驗初步結果後，anito-cel成功的概率已經上調，該試驗針對復發/難治性多發性骨髓瘤患者。市場上具有很大的份額爭奪機會，首先瞄準後期治療階段，如果當前的臨床結果能夠維持，有望擴展至早期階段。
公司的分析表明，最近的摘要涵蓋了初期第2期結果和擴展第1期數據，支持anito-cel在治療多發性骨髓瘤方面的競爭優勢和監管進展。儘管股價下跌，但這被視爲跟隨大幅摘要前上漲的'賣出資訊'事件。預計anito-cel將獲得更具競爭力的市場份額，並更有可能成功。
公司在更新的臨床數據發佈後表達了增加的樂觀情緒。ASH摘要的發佈，尤其是註冊性IMMagine-1研究的初步數據，爲這一積極展望做出了貢獻。
以下爲今日4位分析師對$Arcellx (ACLX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
